DelveInsight’s “Low-Grade Serous Ovarian Carcinoma (LGSOC) — Market Insights, Epidemiology, and Market Forecast — 2032” report delivers an in-depth understanding of the Low-Grade Serous Ovarian Carcinoma, historical and forecasted epidemiology as well as the Low-Grade Serous Ovarian Carcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Low-Grade Serous Ovarian Carcinoma market report provides current treatment practices, emerging drugs, Low-Grade Serous Ovarian Carcinoma market share of the individual therapies, and current and forecasted Low-Grade Serous Ovarian Carcinoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Low-Grade Serous Ovarian Carcinoma treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Low-Grade Serous Ovarian Carcinoma Market Overview
Low-grade serous ovarian carcinoma (LGSOC) is an uncommon (<5%) and under-investigated ovarian cancer type, in some cases arising from serous borderline tumors. In contrast to high-grade serous ovarian cancers (HGSOCs), LGSOCs are TP53 wild-type, do not demonstrate genomic instability or homologous recombination repair deficiency, and frequently harbor classical activating mutations in canonical MAPK pathway components (KRAS, BRAF, and NRAS). LGSOCs typically display high estrogen receptor (ER) expression, with an expression of progesterone receptor (PR) in a subset of cases. Compared with the most common form of ovarian cancer, known as high-grade serous ovarian cancer like pain, bloating, difficulty eating, and bowel and urinary changes as pelvic and abdominal organs are gradually affected. It is thought to start in the ovaries or fallopian tubes and is usually at stages 2 to 4 when it is diagnosed, meaning that it has spread away from the fallopian tubes and ovaries into the pelvis and then the abdomen.
Learn more about the Low-Grade Serous Ovarian Carcinoma market @ Low-Grade Serous Ovarian Carcinoma Market Landscape
Low-Grade Serous Ovarian Carcinoma Epidemiological Segmentation
Low-Grade Serous Ovarian Carcinoma prevalent cases
Low-Grade Serous Ovarian Carcinoma grade-specific cases
Low-Grade Serous Ovarian Carcinoma stage-specific prevelant cases
Low-Grade Serous Ovarian Carcinoma recurrent cases
Low-Grade Serous Ovarian Carcinoma mutation-specific prevalent cases
First-line treatable cases of Low-Grade Serous Ovarian Carcinoma
Low-Grade Serous Ovarian Carcinoma Market Outlook
The current treatment of low-grade serous ovarian carcinoma is mainly dominated by surgery and chemotherapy however, under these regimens, many patients suffer a relapse or develop recurrent tumors that are resistant or refractory to further therapy. The inability of current market offerings to alter the natural course of the disease and improve patients’ quality of life indicates that there is an unmet need for drugs with better efficacy profiles. Surgery remains the mainstay for the initial treatment of Low-Grade Serous Ovarian Carcinoma. At the time of initial presentation, all patients should be evaluated by a gynecologic oncologist for consideration of primary debulking surgery. For selected patients who are deemed inappropriate for primary debulking surgery, due to the extent of disease or comorbidities, neoadjuvant chemotherapy with a platinum/taxane based doublet with interval cytoreductive surgery is considered.
According to DelveInsight, the Low-Grade Serous Ovarian Carcinoma market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies in the Low-Grade Serous Ovarian Carcinoma Market Include:
Pfizer
Context Therapeutics
Merck
And many others
Low Grade Serous Ovarian Carcinoma Therapies Covered and Analyzed in the Report:
MEK162
avutometinib (VS-6766)
Regorafenib
Learn more about the Low-Grade Serous Ovarian Carcinoma Market Key Companies and Emerging Therapies
Table of Contents
Key Insights
Low-Grade Serous Ovarian Carcinoma Report Introduction
Executive Summary of the Low-Grade Serous Ovarian Carcinoma Market
Low-Grade Serous Ovarian Carcinoma Disease Background and Overview
Low-Grade Serous Ovarian Carcinoma Epidemiology and patient population
Low Grade Serous Ovarian Carcinoma Market Emerging Therapies
Low-Grade Serous Ovarian Carcinoma Market Drivers
Low-Grade Serous Ovarian Carcinoma Market Barriers
Market Access and Reimbursement of Therapies
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
Learn more about the detailed report offerings @ Low Grade Serous Ovarian Carcinoma Market Outlook
Trending Reports by DelveInsight
Adalimumab Biosimilar Market
Arbovirus Infection Market
Artificial Pancreas Device System Market
Dental Equipment Market
Gluten Sensitivity Market
Hypothyroidism Market
Inflammatory Bowel Disease Market
Mayus Kinase Jak Inhibitors Market
Mild Dry Eye Market
Mucopolysaccharidosis Market
Oncolytic Virus Cancer Therapy Market
Pyoderma Gangrenosum Market
Transdermal Drug Delivery Devices Market
Intrathecal Pumps Market
Hedgehog Pathway Inhibitors Market
Yellow Fever Market
Laryngeal Cancer Market
Female Infertility Market
Gender Dysphoria Market
Chronic Brain Damage Market
Spain Healthcare Outlook Market
Malignant Fibrous Histiocytoma Market
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
